title: Role of biomarkers in chemotherapy-induced cardiotoxicity.
abstract: Chemotherapy-induced cardiotoxicity remains an unresolved problem strongly impacting the quality of life and the overall survival of cancer patients. The main strategy for minimizing cardiotoxicity is early detection of high-risk patients and prompt prophylactic treatment. The current standard for monitoring cardiac function detects cardiotoxicity only when a functional impairment has already occurred, not allowing for any early preventive strategies. Measurement of cardiospecific biomarkers can be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. In particular, the role of troponin in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing cardiac dysfunction and cardiac events is clearly emerging as a new effective approach. Therefore, we propose troponin as a criterion standard marker for the assessment of cardiac risk of both old and new antineoplastic treatments, and its evaluation should be included among the criteria utilized to define cardiotoxicity.
authors: Cardiology Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy. daniela.cardinale@ieo.it
authors: Daniela
authors: D
authors: Cardinale
authors: Maria Teresa
authors: MT
authors: Sandri
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D042241:Early Diagnosis; D006331:Heart Diseases / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis* / Q000517:prevention & control; D006801:Humans; D045265:Natriuretic Peptides / Q000097:blood; D009369:Neoplasms / Q000188:drug therapy*; D011237:Predictive Value of Tests; D018570:Risk Assessment; D014336:Troponin / Q000097:blood*; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D045265:Natriuretic Peptides; D014336:Troponin